Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Common Equity (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Common Equity for 7 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 89.04% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a 89.04% increase, with the full-year FY2025 number at $1.6 billion, up 89.04% from a year prior.
  • Common Equity was $1.6 billion for Q4 2025 at Kymera Therapeutics, up from $946.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.6 billion in Q4 2025 to a low of $258.1 million in Q2 2021.
  • A 5-year average of $620.1 million and a median of $486.6 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 393.43% in 2021, then fell 22.88% in 2023.
  • Kymera Therapeutics' Common Equity stood at $459.6 million in 2021, then grew by 6.64% to $490.2 million in 2022, then decreased by 19.42% to $395.0 million in 2023, then soared by 111.56% to $835.6 million in 2024, then surged by 89.04% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Common Equity are $1.6 billion (Q4 2025), $946.3 million (Q3 2025), and $971.5 million (Q2 2025).